172 related articles for article (PubMed ID: 22504159)
21. cAMP-induced morphological changes are counteracted by the activated RhoA small GTPase and the Rho kinase ROKalpha.
Dong JM; Leung T; Manser E; Lim L
J Biol Chem; 1998 Aug; 273(35):22554-62. PubMed ID: 9712882
[TBL] [Abstract][Full Text] [Related]
22. Myosin phosphatase and cofilin mediate cAMP/cAMP-dependent protein kinase-induced decline in endothelial cell isometric tension and myosin II regulatory light chain phosphorylation.
Goeckeler ZM; Wysolmerski RB
J Biol Chem; 2005 Sep; 280(38):33083-95. PubMed ID: 16055445
[TBL] [Abstract][Full Text] [Related]
23. Serine phosphorylation negatively regulates RhoA in vivo.
Ellerbroek SM; Wennerberg K; Burridge K
J Biol Chem; 2003 May; 278(21):19023-31. PubMed ID: 12654918
[TBL] [Abstract][Full Text] [Related]
24. [Effect of RhoA and cAMP on morphological changes in human prostate cancer cell line PC-3].
Chen YC; Wang Y; Yu H; Xu WR
Shi Yan Sheng Wu Xue Bao; 2005 Aug; 38(4):363-7. PubMed ID: 16231705
[TBL] [Abstract][Full Text] [Related]
25. RhoA/ROCK activation by growth hormone abrogates p300/histone deacetylase 6 repression of Stat5-mediated transcription.
Ling L; Lobie PE
J Biol Chem; 2004 Jul; 279(31):32737-50. PubMed ID: 15102857
[TBL] [Abstract][Full Text] [Related]
26. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.
Berenguer C; Boudouresque F; Dussert C; Daniel L; Muracciole X; Grino M; Rossi D; Mabrouk K; Figarella-Branger D; Martin PM; Ouafik L
Oncogene; 2008 Jan; 27(4):506-18. PubMed ID: 17637748
[TBL] [Abstract][Full Text] [Related]
27. Protein kinase A (PKA) pathway is functionally linked to androgen receptor (AR) in the progression of prostate cancer.
Sarwar M; Sandberg S; Abrahamsson PA; Persson JL
Urol Oncol; 2014 Jan; 32(1):25.e1-12. PubMed ID: 23410945
[TBL] [Abstract][Full Text] [Related]
28. Vasoactive intestinal peptide induces neuroendocrine differentiation in the LNCaP prostate cancer cell line through PKA, ERK, and PI3K.
Gutiérrez-Cañas I; Juarranz MG; Collado B; Rodríguez-Henche N; Chiloeches A; Prieto JC; Carmena MJ
Prostate; 2005 Apr; 63(1):44-55. PubMed ID: 15468165
[TBL] [Abstract][Full Text] [Related]
29. Coordinated regulation of Rap1 and thyroid differentiation by cyclic AMP and protein kinase A.
Tsygankova OM; Saavedra A; Rebhun JF; Quilliam LA; Meinkoth JL
Mol Cell Biol; 2001 Mar; 21(6):1921-9. PubMed ID: 11238928
[TBL] [Abstract][Full Text] [Related]
30. AMPK/SIRT1 signaling through p38MAPK mediates Interleukin-6 induced neuroendocrine differentiation of LNCaP prostate cancer cells.
Natani S; Dhople VM; Parveen A; Sruthi KK; Khilar P; Bhukya S; Ummanni R
Biochim Biophys Acta Mol Cell Res; 2021 Sep; 1868(10):119085. PubMed ID: 34171447
[TBL] [Abstract][Full Text] [Related]
31. Serine phosphorylation differentially affects RhoA binding to effectors: implications to NGF-induced neurite outgrowth.
Nusser N; Gosmanova E; Makarova N; Fujiwara Y; Yang L; Guo F; Luo Y; Zheng Y; Tigyi G
Cell Signal; 2006 May; 18(5):704-14. PubMed ID: 16109481
[TBL] [Abstract][Full Text] [Related]
32. Phosphorylation of mitogen-activated protein kinase is inhibited by calcitonin in DU145 prostate cancer cells.
Segawa N; Nakamura M; Nakamura Y; Mori I; Katsuoka Y; Kakudo K
Cancer Res; 2001 Aug; 61(16):6060-3. PubMed ID: 11507054
[TBL] [Abstract][Full Text] [Related]
33. Cyclic AMP dysregulates intestinal epithelial cell restitution through PKA and RhoA.
Zimmerman NP; Kumar SN; Turner JR; Dwinell MB
Inflamm Bowel Dis; 2012 Jun; 18(6):1081-91. PubMed ID: 21993975
[TBL] [Abstract][Full Text] [Related]
34. Dual effect of pituitary adenylate cyclase activating polypeptide on prostate tumor LNCaP cells: short- and long-term exposure affect proliferation and neuroendocrine differentiation.
Farini D; Puglianiello A; Mammi C; Siracusa G; Moretti C
Endocrinology; 2003 Apr; 144(4):1631-43. PubMed ID: 12639948
[TBL] [Abstract][Full Text] [Related]
35. Neuronal Trans-Differentiation in Prostate Cancer Cells.
Farach A; Ding Y; Lee M; Creighton C; Delk NA; Ittmann M; Miles B; Rowley D; Farach-Carson MC; Ayala GE
Prostate; 2016 Oct; 76(14):1312-25. PubMed ID: 27403603
[TBL] [Abstract][Full Text] [Related]
36. Regulation of RhoA signaling by the cAMP-dependent phosphorylation of RhoGDIα.
Oishi A; Makita N; Sato J; Iiri T
J Biol Chem; 2012 Nov; 287(46):38705-15. PubMed ID: 23012358
[TBL] [Abstract][Full Text] [Related]
37. AKAPs competing peptide HT31 disrupts the inhibitory effect of PKA on RhoA activity.
Wang Y; Chen Y; Chen M; Xu W
Oncol Rep; 2006 Oct; 16(4):755-61. PubMed ID: 16969490
[TBL] [Abstract][Full Text] [Related]
38. Ste20-related kinase SLK phosphorylates Ser188 of RhoA to induce vasodilation in response to angiotensin II Type 2 receptor activation.
Guilluy C; Rolli-Derkinderen M; Loufrani L; Bourgé A; Henrion D; Sabourin L; Loirand G; Pacaud P
Circ Res; 2008 May; 102(10):1265-74. PubMed ID: 18420945
[TBL] [Abstract][Full Text] [Related]
39. PKA inhibits RhoA activation: a protection mechanism against endothelial barrier dysfunction.
Qiao J; Huang F; Lum H
Am J Physiol Lung Cell Mol Physiol; 2003 Jun; 284(6):L972-80. PubMed ID: 12588708
[TBL] [Abstract][Full Text] [Related]
40. Rho/ROCK/actin signaling regulates membrane androgen receptor induced apoptosis in prostate cancer cells.
Papadopoulou N; Charalampopoulos I; Alevizopoulos K; Gravanis A; Stournaras C
Exp Cell Res; 2008 Oct; 314(17):3162-74. PubMed ID: 18694745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
